Skip to content

希邦医疗

US · SIBN #3357 按市值排名 上市于 2018
19.68 -0.23 -1.16%
实时 - 追踪5344个代码 - 心跳于23秒前 · 2026-10-16 20:02

估值 各估值倍数与自身5年区间的对比

市净率 4.69 处于历史正常水平 第63百分位
5年平均 4.73 · 在Medical Devices中排名第89/125
市盈率 -57.88 低于历史水平 第1百分位
5年平均 -19.73 · 前瞻 -49.03
市销率 4.01 低于历史水平 第32百分位
5年平均 5.23 · 前瞻 3.41 · 在Medical Devices中排名第88/136

同业对比 Medical Devices

公司 市值 市盈率(TTM) 市净率 股息率
希邦医疗 (SIBN) 882.03M -59.64 4.84 0.00%
Abbott Laboratories (ABT) 181.50B 33.94 3.55 2.33%
Medtronic (MDT) 121.20B 23.34 2.41 3.01%
Stryker Corp (SYK) 113.02B 30.53 4.71 1.18%
Boston Scientific (BSX) 64.33B 17.97 2.58 0.00%
Edwards Lifesciences (EW) 49.92B 50.35 4.70 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值16.69 经济护城河None 不确定性High

当前股价高于晨星合理价值估算15.2%。

合理价值

SI-BONE Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 14% premium over our quantitative fair value estimate of $16.69 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The firm's valuation metrics decrease our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to EBITDA ratio of 55.1 sits in the top 10% compared with global peers. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. We believe this is a sign that shares could be overvalued.

The company's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 1.4%, a core component of profitability, sits in the bottom 40% globally. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

经济护城河

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 20:02:21 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

希邦医疗 讨论区 0 条评论

发表评论